91��Ƭ������AV

"Venture Partners at CU Boulder has announced the first recipients of a new translational funding program designed to advance promising, early-stage therapeutics with strong commercial potential...Led by Distinguished Professor Leslie Leinwand (BioFrontiers Institute, CU Boulder Molecular, Cellular & Developmental Biology), with PhD student Jack Gugel and postdoctoral researchers Thomas Martin and Yuxiao Tan, the team is developing an orally available obesity drug that suppresses appetite without affecting gastric emptying or causing muscle loss."

"Dr. Edward Chuong is investigating the unexpected role of transposons in shaping immune responses and potentially influencing cancer immunotherapy outcomes. Long considered genomic “junk” or inert fossils, transposons – mobile genetic elements that make up over 50% of the human genome – are now emerging as important regulators of host gene expression. Dr. Chuong’s research has revealed that transposon-derived regulatory elements have been co-opted as enhancers and transcriptional switches, playing essential roles in innate immune signaling across multiple mammalian lineages, including primates, rodents, and bats."

Debanjan Mukherjee (MCEN) and Sammy Ramsey (EBIO) are two of the winners of the CU Research & Innovation Office's 2025 Seed Grants.